Les nouvelles indications en oncologie peu accessibles au patient français
Une étude réalisée par Prioritis pour le G5 Santé et le Leem a permis de mettre en évidence l'accès difficile...
06
Oct
09
Oct
Evaluation du médicament au Japon dans Prismaccess
Prioritis a le plaisir d'annoncer l'intégration des décisions japonaises en matière de remboursement, de prix et d'accès dans Prismaccess et...
Prioritis at ISPOR Baltimore
ISPOR 23rd Annual International Meeting is almost here and Prioritis is happy to announce it’s first participation in Baltimore! Our International...
26
Feb
Spain, a new financing model for high economic-impact medicines
The Dirección de la Cartera Básica de Servicios del SNS y Farmacia, has announced the start-up of a new financing...
19
Feb
Données Prismaccess dans une étude de l’INCa
Une étude internationale, menée par l’Institut National du Cancer (INCa), a notamment utilisé les informations des bases Prismaccess et Evalumade....
31
Jan
RWD and RWE will play an increasing role in health care decisions
Real World Data (RWD) and Real World Evidence (RWE) will be surely changing the way we track medicine's efficacy and...
09
Jan
PRIORITIS heads a market access training at Paris-Dauphine University
PRIORITIS has been chosen for its exceptional knowledge and understanding of market access strategies to lead a series of courses...
30
Nov
Peru’s HTA Agency reports in Prismaccess & Evalumade platforms
Prioritis is pleased to announce the addition of another HTA agency to our Prismaccess/Evalumade database: the Institute for the Evaluation...
23
Oct
Singapore’s HTA decisions in Prismaccess and Evalumade
Considered to be one of the best health-care systems in the world, Singapore is a model of quality, efficiency and...
20
Oct
ISPOR 20th Annual European Congress
4-8 November 2017 – Glasgow We are looking forward to meeting you during the ISPOR Congress and present you our unique...